Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07168486	CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas	enrolling by invitation	Phase 1	15	University of Maryland, BaltimoreOTHER	1	Sep 14, 2026	clinicaltrials
NCT06871007	Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma	enrolling by invitation	Phase 1 / Phase 2	22	St. Petersburg State Pavlov Medical UniversityOTHER	1	Mar 11, 2025	clinicaltrials